This conference brings together academic and industry scientists at the forefront of biologics discovery and engineering for autoimmune indications, where the bar for safety, selectivity, and sustained effect is uniquely demanding. Sessions will explore how the field is adapting modalities pioneered in oncology, developing multi-target strategies, and tackling the specific challenges of intermittent dosing, target coverage, and cytokine safety that define success in immunology and inflammation.
